Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DR26FKJG1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,795
Award facts
- Contract value 100% obligated
- $5,795.49 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,795.49 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injector. The award was issued on October 28, 2025, under a firm fixed-price contract type with an ultimate completion date of October 29, 2025. No set-aside designation was utilized for this award. DMS Pharmaceutical Group Inc., which has been registered in the System for Award Management since July 2001, serves as a critical supplier within the federal pharmaceutical supply chain, particularly for the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy. The underlying IDC, designated SPE2DR and awarded in November 2025, carries a ceiling value of $499.999 billion and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. As one of multiple regional prime vendor contractors under this program, DMS Pharmaceutical Group is authorized to supply a broad range of pharmaceutical products, including branded and generic prescription medications, biologics, and medical consumables to support Department of Defense healthcare operations globally. The company has demonstrated substantial federal contracting capability across multiple therapeutic categories and continues to fulfill critical pharmaceutical supply requirements for military healthcare facilities.
Quick answers
Who was awarded contract SPE2DR26FKJG1?
SPE2DR26FKJG1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DR26FKJG1 worth?
The government has obligated $5,795 on SPE2DR26FKJG1.
Is contract SPE2DR26FKJG1 an order under another contract?
Yes. SPE2DR26FKJG1 is a delivery order under SPE2DR25D9105, an indefinite delivery contract.
Was contract SPE2DR26FKJG1 competed?
The extent of competition for SPE2DR26FKJG1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award